Shradha Infraprojects Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 19, 2025, 10:33 pm

Competitors of Shradha Infraprojects Ltd

All Competitor Stocks of Shradha Infraprojects Ltd

Quarterly Result

Last Updated: August 20, 2025, 3:45 am

Below is a detailed analysis of the quarterly data for Shradha Infraprojects Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 26.18 Cr.. The value appears to be declining and may need further review. It has decreased from 42.61 Cr. (Mar 2025) to 26.18 Cr., marking a decrease of 16.43 Cr..
• For Expenses, as of Jun 2025, the value is 19.43 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 29.82 Cr. (Mar 2025) to 19.43 Cr., marking a decrease of 10.39 Cr..
• For Operating Profit, as of Jun 2025, the value is 6.75 Cr.. The value appears to be declining and may need further review. It has decreased from 12.79 Cr. (Mar 2025) to 6.75 Cr., marking a decrease of 6.04 Cr..
• For OPM %, as of Jun 2025, the value is 25.78%. The value appears to be declining and may need further review. It has decreased from 30.02% (Mar 2025) to 25.78%, marking a decrease of 4.24%.
• For Other Income, as of Jun 2025, the value is 1.94 Cr.. The value appears strong and on an upward trend. It has increased from 1.36 Cr. (Mar 2025) to 1.94 Cr., marking an increase of 0.58 Cr..
• For Interest, as of Jun 2025, the value is 0.88 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 3.01 Cr. (Mar 2025) to 0.88 Cr., marking a decrease of 2.13 Cr..
• For Depreciation, as of Jun 2025, the value is 0.82 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.11 Cr. (Mar 2025) to 0.82 Cr., marking a decrease of 0.29 Cr..
• For Profit before tax, as of Jun 2025, the value is 6.99 Cr.. The value appears to be declining and may need further review. It has decreased from 10.03 Cr. (Mar 2025) to 6.99 Cr., marking a decrease of 3.04 Cr..
• For Tax %, as of Jun 2025, the value is 25.75%. The value appears to be increasing, which may not be favorable. It has increased from 25.22% (Mar 2025) to 25.75%, marking an increase of 0.53%.
• For Net Profit, as of Jun 2025, the value is 5.19 Cr.. The value appears to be declining and may need further review. It has decreased from 7.50 Cr. (Mar 2025) to 5.19 Cr., marking a decrease of 2.31 Cr..
• For EPS in Rs, as of Jun 2025, the value is 0.75. The value appears to be declining and may need further review. It has decreased from 1.08 (Mar 2025) to 0.75, marking a decrease of 0.33.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: November 15, 2025, 4:28 am

Growth

Last Updated: September 5, 2025, 1:26 pm

Balance Sheet

Last Updated: June 16, 2025, 11:22 am

Below is a detailed analysis of the balance sheet data for Shradha Infraprojects Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 10.00 Cr..
• For Reserves, as of Mar 2025, the value is 142.00 Cr.. The value appears strong and on an upward trend. It has increased from 82.00 Cr. (Mar 2024) to 142.00 Cr., marking an increase of 60.00 Cr..
• For Borrowings, as of Mar 2025, the value is 170.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 152.00 Cr. (Mar 2024) to 170.00 Cr., marking an increase of 18.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 78.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 45.00 Cr. (Mar 2024) to 78.00 Cr., marking an increase of 33.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 400.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 288.00 Cr. (Mar 2024) to 400.00 Cr., marking an increase of 112.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 48.00 Cr.. The value appears strong and on an upward trend. It has increased from 38.00 Cr. (Mar 2024) to 48.00 Cr., marking an increase of 10.00 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 9.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 9.00 Cr..
• For Investments, as of Mar 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 2.00 Cr..
• For Other Assets, as of Mar 2025, the value is 350.00 Cr.. The value appears strong and on an upward trend. It has increased from 238.00 Cr. (Mar 2024) to 350.00 Cr., marking an increase of 112.00 Cr..
• For Total Assets, as of Mar 2025, the value is 400.00 Cr.. The value appears strong and on an upward trend. It has increased from 288.00 Cr. (Mar 2024) to 400.00 Cr., marking an increase of 112.00 Cr..

However, the Borrowings (170.00 Cr.) are higher than the Reserves (142.00 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Shradha Infraprojects Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 5.00 (Mar 24) to 2.00, marking a decrease of 3.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 3.64. This value is below the healthy minimum of 5. It has decreased from 9.20 (Mar 24) to 3.64, marking a decrease of 5.56.
• For Diluted EPS (Rs.), as of Mar 25, the value is 3.64. This value is below the healthy minimum of 5. It has decreased from 9.20 (Mar 24) to 3.64, marking a decrease of 5.56.
• For Cash EPS (Rs.), as of Mar 25, the value is 5.18. This value is within the healthy range. It has decreased from 11.59 (Mar 24) to 5.18, marking a decrease of 6.41.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 30.12. It has decreased from 46.02 (Mar 24) to 30.12, marking a decrease of 15.90.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 30.12. It has decreased from 46.02 (Mar 24) to 30.12, marking a decrease of 15.90.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 21.05. It has decreased from 54.54 (Mar 24) to 21.05, marking a decrease of 33.49.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 7.42. This value is within the healthy range. It has decreased from 13.98 (Mar 24) to 7.42, marking a decrease of 6.56.
• For PBIT / Share (Rs.), as of Mar 25, the value is 6.61. This value is within the healthy range. It has decreased from 12.28 (Mar 24) to 6.61, marking a decrease of 5.67.
• For PBT / Share (Rs.), as of Mar 25, the value is 5.95. This value is within the healthy range. It has decreased from 12.21 (Mar 24) to 5.95, marking a decrease of 6.26.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 4.36. This value is within the healthy range. It has decreased from 9.89 (Mar 24) to 4.36, marking a decrease of 5.53.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 3.64. This value is within the healthy range. It has decreased from 9.21 (Mar 24) to 3.64, marking a decrease of 5.57.
• For PBDIT Margin (%), as of Mar 25, the value is 35.25. This value is within the healthy range. It has increased from 25.63 (Mar 24) to 35.25, marking an increase of 9.62.
• For PBIT Margin (%), as of Mar 25, the value is 31.39. This value exceeds the healthy maximum of 20. It has increased from 22.51 (Mar 24) to 31.39, marking an increase of 8.88.
• For PBT Margin (%), as of Mar 25, the value is 28.28. This value is within the healthy range. It has increased from 22.37 (Mar 24) to 28.28, marking an increase of 5.91.
• For Net Profit Margin (%), as of Mar 25, the value is 20.72. This value exceeds the healthy maximum of 10. It has increased from 18.12 (Mar 24) to 20.72, marking an increase of 2.60.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 17.30. This value is within the healthy range. It has increased from 16.88 (Mar 24) to 17.30, marking an increase of 0.42.
• For Return on Networth / Equity (%), as of Mar 25, the value is 12.09. This value is below the healthy minimum of 15. It has decreased from 20.31 (Mar 24) to 12.09, marking a decrease of 8.22.
• For Return on Capital Employeed (%), as of Mar 25, the value is 15.66. This value is within the healthy range. It has decreased from 19.00 (Mar 24) to 15.66, marking a decrease of 3.34.
• For Return On Assets (%), as of Mar 25, the value is 4.60. This value is below the healthy minimum of 5. It has decreased from 6.47 (Mar 24) to 4.60, marking a decrease of 1.87.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.13. This value is below the healthy minimum of 0.2. It has decreased from 0.38 (Mar 24) to 0.13, marking a decrease of 0.25.
• For Total Debt / Equity (X), as of Mar 25, the value is 1.11. This value exceeds the healthy maximum of 1. It has decreased from 1.65 (Mar 24) to 1.11, marking a decrease of 0.54.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.30. It has decreased from 0.40 (Mar 24) to 0.30, marking a decrease of 0.10.
• For Current Ratio (X), as of Mar 25, the value is 1.86. This value is within the healthy range. It has increased from 1.51 (Mar 24) to 1.86, marking an increase of 0.35.
• For Quick Ratio (X), as of Mar 25, the value is 0.73. This value is below the healthy minimum of 1. It has increased from 0.21 (Mar 24) to 0.73, marking an increase of 0.52.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.51. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 0.51, marking an increase of 0.51.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 10.97. This value is below the healthy minimum of 20. It has increased from 2.71 (Mar 24) to 10.97, marking an increase of 8.26.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 8.97. This value is below the healthy minimum of 20. It has increased from 2.29 (Mar 24) to 8.97, marking an increase of 6.68.
• For Earning Retention Ratio (%), as of Mar 25, the value is 89.03. This value exceeds the healthy maximum of 70. It has decreased from 97.29 (Mar 24) to 89.03, marking a decrease of 8.26.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 91.03. This value exceeds the healthy maximum of 70. It has decreased from 97.71 (Mar 24) to 91.03, marking a decrease of 6.68.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 11.34. This value is within the healthy range. It has decreased from 191.85 (Mar 24) to 11.34, marking a decrease of 180.51.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.67. This value is within the healthy range. It has decreased from 136.62 (Mar 24) to 7.67, marking a decrease of 128.95.
• For Enterprise Value (Cr.), as of Mar 25, the value is 458.89. It has increased from 282.64 (Mar 24) to 458.89, marking an increase of 176.25.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.31. This value exceeds the healthy maximum of 3. It has increased from 2.56 (Mar 24) to 4.31, marking an increase of 1.75.
• For EV / EBITDA (X), as of Mar 25, the value is 12.21. This value is within the healthy range. It has increased from 9.98 (Mar 24) to 12.21, marking an increase of 2.23.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.94. This value is within the healthy range. It has increased from 1.20 (Mar 24) to 2.94, marking an increase of 1.74.
• For Retention Ratios (%), as of Mar 25, the value is 89.02. This value exceeds the healthy maximum of 70. It has decreased from 97.28 (Mar 24) to 89.02, marking a decrease of 8.26.
• For Price / BV (X), as of Mar 25, the value is 2.06. This value is within the healthy range. It has increased from 1.45 (Mar 24) to 2.06, marking an increase of 0.61.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.94. This value is within the healthy range. It has increased from 1.20 (Mar 24) to 2.94, marking an increase of 1.74.
• For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has decreased from 0.14 (Mar 24) to 0.05, marking a decrease of 0.09.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness